Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market is projected to reach US$ 2107.8 million in 2034, increasing from US$ 2363 million in 2022, with the CAGR of -1.6% during the period of 2024 to 2034. Demand from Acute CINV and Delayed CINV are the major drivers for the industry.
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.
North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Others
Acute CINV
Delayed CINV
Breakthrough CINV
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs introduction, etc. Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market is projected to reach US$ 2107.8 million in 2034, increasing from US$ 2363 million in 2022, with the CAGR of -1.6% during the period of 2024 to 2034. Demand from Acute CINV and Delayed CINV are the major drivers for the industry.
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.
North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Others
Segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs introduction, etc. Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices